The DoDo experience: an alternative antiretroviral 2-drug regimen of doravirine and dolutegravir

Infection. 2023 Dec;51(6):1823-1829. doi: 10.1007/s15010-023-02075-y. Epub 2023 Aug 1.


Background: Currently available antiretroviral 2-drug regimen (2DR) fixed dose combinations may not be suitable for specific situations including the presence of resistance associated mutations (RAM) or drug - drug interactions (DDI). The data on the use of the non-nucleoside reverse transcriptase inhibitor doravirine (DOR) and the integrase inhibitor dolutegravir (DTG) as an alternative 2DR remain scarce.

Methods: People living with HIV with DOR + DTG as a 2DR are being followed in a prospective observational study.

Results: This analysis describes 85 participants with a median age of 57 years. Median CD4-nadir was 173/µl and a majority (66%) had a history of HIV-associated or AIDS-defining conditions. Antiretroviral history was mostly extensive, and documentation of RAM was frequent. The main reasons for choosing DOR + DTG were DDI (29%), tolerability (25%), and cardiovascular risk reduction (21%). Plasma viral load at switch was < 50 copies/ml in all but 3 instances, median CD4 count was 600/µl. DOR + DTG was later changed to another regimen in 10 participants after a median of 265 days, the other 75 participants have remained on DOR + DTG for a median of 947 days.

Conclusion: DOR + DTG as a 2DR proved to be a durable treatment option even in extensively pretreated individuals.

Keywords: 2-drug regimen; Antiretroviral therapy; Dolutegravir; Doravirine; HIV.

Publication types

  • Observational Study

MeSH terms

  • Acquired Immunodeficiency Syndrome* / drug therapy
  • Anti-HIV Agents* / therapeutic use
  • Anti-Retroviral Agents / therapeutic use
  • HIV Infections* / drug therapy
  • Humans
  • Middle Aged
  • Oxazines / therapeutic use
  • Treatment Outcome
  • Viral Load


  • doravirine
  • dolutegravir
  • Anti-Retroviral Agents
  • Oxazines
  • Anti-HIV Agents